The story so far
Trump Generic Drug Tariff Plan
Tracked across 9 sources · Updated 4h ago
Trump announced a phased tariff on imported generic drugs: 0% for two years, then 100% from August 2028, rising to 200% from August 2029. The aim is to encourage domestic production. Indian pharma stocks fell, but analysts note India's cost advantage may cushion impact.
How it unfolded
1d ago
Analysts say India's cost edge may limit impact
1d ago
Indian pharma leaders say tariffs impossible to absorb
1d ago
Indian pharma stocks fall over 2% after tariff announcement
1d ago
Details emerge: 0% for 2 years, then 100-200% tariff
2d ago
Trump announces 100% tariff on imported generic drugs from August 2028
What happened earlier
Latest updates
Latest
Full story →Pharma companies in a flux over Trump's 200% tariff move on generics
US President Donald Trump announced 100% tariffs on generic medicines from Aug 2028 and 200% from Aug 2029, unless companies move manufacturing to the US.
India supplies 47% of generic prescriptions in the US and ships $10 billion in pharma exports there, making it heavily exposed.
A two-year exemption window gives Indian exporters time to adjust supply chains, but industry experts see the move as a negotiating lever.
Companies like Sun Pharma, Dr Reddy's Labs, and Cipla, with 35-50% US revenue, face higher impact but some have US facilities to mitigate.
High tariffs could raise US medicine prices and cause shortages, as key ingredients come from China and India, not replicable quickly in the US.
Earlier · 1d ago
Full story →Trump Says Imported Generic Drugs To Face 100% Tariff From August 2028
US President Donald Trump announced 100% tariffs on imported generic drugs starting August 2028.
The move aims to bring pharmaceutical production back to the US.
The tariffs specifically target generic drugs, not branded or patented medications.
Earlier · 1d ago
Full story →Trump Announces 0% US Tariff on Generic Drugs For Two Years, Then 100% And 200% Tariffs Later
President Trump proposes 0% tariff on generic drugs for two years, then 100% and 200% tariffs thereafter.
The policy aims to incentivize pharmaceutical manufacturing to relocate to the United States.
India, a major exporter of generic medicines, would be significantly affected by the tariff changes.
Earlier · 21h ago
Full story →Indian pharma stocks tumble on Trump's generic drug tariff plan
Indian pharma stocks fell after Trump announced phased tariffs on generic drugs.
Expert analysis suggests minimal impact due to India's manufacturing cost advantage.
US subsidiaries of Indian firms and regulatory hurdles for shifting production mitigate effects.
The tariff plan targets reducing reliance on foreign drug manufacturing.
Earlier · 17h ago
Full story →Stocks making the biggest moves midday: Bajaj Auto, TVS Motor, Bandhan Bank, MTAR Tech, Nestle and more
Donald Trump proposed a 200% tariff on generic drug imports, affecting pharma exporters.
Bandhan Bank faced severe selling pressure at midday.
Nestle India shares rose significantly due to strong Q1 corporate earnings.
TVS Motor and Bajaj Auto shares gained sharply on robust quarterly results.
MTAR Tech also saw notable stock movement amid the market action.